# Semaglutide ```text DRUG INFORMATION ADULT - • Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2.1). • Inject subcutaneously in the abdomen, thigh or upper arm (2.1). • In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment (2.1). • Initiate at 0.25 mg once weekly for 4 weeks. Source: US FDA label for semaglutide (WEGOVY), section 'dosage and administration', retrieved 2026-08-29 - Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage (2.2 , 2.3). • The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) . • The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly (2.3). Source: US FDA label for semaglutide (WEGOVY), section 'dosage and administration', retrieved 2026-08-29 - The time of day and the injection site can be changed without dose adjustment. 2.2 Recommended Dosage in Adults Dosage Initiation and Escalation • Initiate WEGOVY with a dosage of 0.25 mg injected subcutaneously once weekly. Source: US FDA label for semaglutide (WEGOVY), section 'dosage and administration', retrieved 2026-08-29 CHILD - The safety and effectiveness of WEGOVY as an adjunct to a reduced calorie diet and increased physical activity for weight reduction and long-term maintenance have been established in pediatric patients aged 12 years and older with obesity. Source: US FDA label for semaglutide (WEGOVY), section 'pediatric use', retrieved 2026-08-29 - • Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2.1). • Inject subcutaneously in the abdomen, thigh or upper arm (2.1). • In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment (2.1). • Initiate at 0.25 mg once weekly for 4 weeks. Source: US FDA label for semaglutide (WEGOVY), section 'dosage and administration', retrieved 2026-08-29 - Then follow the dosage escalation schedule, titrating every 4 weeks to achieve the maintenance dosage (2.2 , 2.3). • The maintenance dosage of WEGOVY in adults is either 2.4 mg (recommended) or 1.7 mg once weekly (2.2) . • The maintenance dosage of WEGOVY in pediatric patients aged 12 years and older is 2.4 mg once weekly (2.3). Source: US FDA label for semaglutide (WEGOVY), section 'dosage and administration', retrieved 2026-08-29 RENAL IMPAIRMENT - Patients aged 75 years and older (WEGOVY-treated and placebo-treated) reported more serious adverse reactions overall compared to younger adult patients [see Adverse Reactions (6.1) ]. 8.6 Renal Impairment No dose adjustment of WEGOVY is recommended for patients with renal impairment. Source: US FDA label for semaglutide (WEGOVY), section 'use in specific populations', retrieved 2026-08-29 - In a study in patients with renal impairment, including end-stage renal disease, no clinically relevant change in semaglutide pharmacokinetics was observed [see Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment No dose adjustment of WEGOVY is recommended for patients with hepatic impairment. Source: US FDA label for semaglutide (WEGOVY), section 'use in specific populations', retrieved 2026-08-29 - Monitor renal function when initiating or escalating doses of WEGOVY in patients reporting severe adverse gastrointestinal reactions or in those with renal impairment reporting severe adverse gastrointestinal reactions ( 5.5 ). • Hypersensitivity Reactions: Anaphylactic reactions and angioedema have been reported postmarketing. Source: US FDA label for semaglutide (WEGOVY), section 'warnings and cautions', retrieved 2026-08-29 HEPATIC IMPAIRMENT - In a study in patients with renal impairment, including end-stage renal disease, no clinically relevant change in semaglutide pharmacokinetics was observed [see Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment No dose adjustment of WEGOVY is recommended for patients with hepatic impairment. Source: US FDA label for semaglutide (WEGOVY), section 'use in specific populations', retrieved 2026-08-29 - In a study in patients with different degrees of hepatic impairment, no clinically relevant change in semaglutide pharmacokinetics was observed [see Clinical Pharmacology ( 12.3 )] . Source: US FDA label for semaglutide (WEGOVY), section 'use in specific populations', retrieved 2026-08-29 PREGNANCY - Pregnancy Exposure Registry There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide during pregnancy. Source: US FDA label for semaglutide (WEGOVY), section 'pregnancy', retrieved 2026-08-29 - Pregnant women exposed to WEGOVY and healthcare providers are encouraged to contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com. Source: US FDA label for semaglutide (WEGOVY), section 'pregnancy', retrieved 2026-08-29 - Risk Summary Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. Source: US FDA label for semaglutide (WEGOVY), section 'pregnancy', retrieved 2026-08-29 BREASTFEEDING - Pharmacologically mediated marked initial maternal body weight loss and reductions in body weight gain and food consumption coincided with an increase in early pregnancy losses and led to delivery of slightly smaller offspring at greater than or equal to 0.075 mg/kg twice weekly (greater than or equal to 1-time human exposure). Source: US FDA label for semaglutide (WEGOVY), section 'use in specific populations', retrieved 2026-08-29 - When a drug is present in animal milk, it is likely that the drug will be present in human milk ( see Data ) . Source: US FDA label for semaglutide (WEGOVY), section 'use in specific populations', retrieved 2026-08-29 - The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for WEGOVY and any potential adverse effects on the breastfed infant from WEGOVY or from the underlying maternal condition. Source: US FDA label for semaglutide (WEGOVY), section 'use in specific populations', retrieved 2026-08-29 ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)